Environmental

TPST’s environmental profile is limited by its preclinical biotech model, which keeps direct emissions and resource intensity structurally lower than manufacturing-heavy peers.

The company discloses no material environmental operations in the provided metrics, so its relative position is broadly neutral versus similarly early-stage biotech peers.

Absence of meaningful R&D intensity in the supplied data suggests a lighter physical footprint, but it also limits evidence of proactive environmental management versus better-disclosed peers.

Compared with larger life-science peers that publish more detailed sustainability controls, TPST appears less transparent on environmental governance, which weakens relative ESG visibility.

Social

TPST’s social profile is constrained by its early-stage status, because limited commercial operations reduce workforce and product-access exposures relative to scaled biotech peers.

The provided metrics show no stock-based compensation burden, which may indicate lower dilution-related employee alignment concerns than peers with heavier equity-based pay.

However, the absence of disclosed social metrics in the supplied data limits assessment of labor practices, diversity, and patient-impact governance versus more transparent peers.

Relative to established biotech companies with broader clinical and stakeholder footprints, TPST’s social risk is smaller in scale but also less evidenced and less mature.

Governance

TPST’s governance profile is mixed because the negative debt-to-equity ratio suggests a net cash position, which is generally stronger than leveraged peers.

The zero stock-based compensation metric in the supplied data points to lower equity dilution pressure than many development-stage biotech peers, supporting shareholder alignment.

At the same time, the lack of disclosed governance detail in the provided information limits confidence in board oversight, controls, and disclosure quality versus better-reporting peers.

Relative to peers, TPST appears financially conservative but governance visibility remains thin, preventing a stronger score despite the absence of obvious leverage stress.

Overall Score

TPST’s ESG positioning is broadly average versus early-stage biotech peers, with low operational environmental and social exposure offset by limited disclosure depth.

Score Driver: Limited ESG Disclosure And Transparency Versus Better-Reporting Peers.